Therapies targeting mismatch repair, such as small-molecule MSH3 inhibitors or ASOs, represent a promising avenue for combating HD at its genetic roots (Moss et al. 2017; Iyer and Pluciennik 2021). This evidence concerns the gene MSH3 and Huntington disease.